SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial Journal: Signal Transduction and Targeted Therapy Author: Yao, H., Yan, M., Tong, Z. et al., China The novel HER2-targeting antibody-drug conjugate SHR-A1811 has demonstrated remarkable long-term efficacy and a manageable safety profile in patients with heavily pre-treated advanced solid […]